EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Developing Folate-Conjugated miR-34a Therapeutic for Prostate Cancer: Challenges and Promises

Wen Jess Li iD, Yunfei Wang, Xiaozhuo Liu iD, Shan Wu, Moyi Wang, Steven G Turowski, Joseph A Spernyak iD, Amanda Tracz, Ahmed M Abdelaal iD, Kasireddy Sudarshan iD, Igor Puzanov iD, Gurkamal Chatta und 2 weitere

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25042123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Wen Jess Li und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA. Hauptthemen laut MEDLINE: Lung Neoplasms, MicroRNAs, Prostatic Neoplasms, Folic Acid. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, U.S National Institutes of Health (NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer (PCa) remains a common cancer with high mortality in men due to its heterogeneity and the emergence of drug resistance. A critical factor contributing to its lethality is the presence of prostate cancer stem cells (PCSCs), which can self-renew, long-term propagate tumors, and mediate treatment resistance. MicroRNA-34a (miR-34a) has shown promise as an anti-PCSC therapeutic by targeting critical molecules involved in cancer stem cell (CSC) survival and functions. Despite extensive efforts, the development of miR-34a therapeutics still faces challenges, including non-specific delivery and delivery-associated toxicity. One emerging delivery approach is ligand-mediated conjugation, aiming to achieve specific delivery of miR-34a to cancer cells, thereby enhancing efficacy while minimizing toxicity. Folate-conjugated miR-34a (folate–miR-34a) has demonstrated promising anti-tumor efficacy in breast and lung cancers by targeting folate receptor α (FOLR1). Here, we first show that miR-34a, a TP53 transcriptional target, is reduced in PCa that harbors TP53 loss or mutations and that miR-34a mimic, when transfected into PCa cells, downregulated multiple miR-34a targets and inhibited cell growth. When exploring the therapeutic potential of folate–miR-34a, we found that folate–miR-34a exhibited impressive inhibitory effects on breast, ovarian, and cervical cancer cells but showed minimal effects on and targeted delivery to PCa cells due to a lack of appreciable expression of FOLR1 in PCa cells. Folate–miR-34a also did not display any apparent effect on PCa cells expressing prostate-specific membrane antigen (PMSA) despite the reported folate’s binding capability to PSMA. These results highlight challenges in the specific delivery of folate–miR-34a to PCa due to a lack of target (receptor) expression. Our study offers novel insights into the challenges and promises within the field and casts light on the development of ligand-conjugated miR-34a therapeutics for PCa.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsMicroRNAsProstatic NeoplasmsFolic AcidHumansMaleCell Line, TumorCell ProliferationFolate Receptor 1Gene Expression Regulation, NeoplasticLigands

Stichwörter der Autor:innen

PSMAcancer stem cellsfolate receptormiRNA ligand conjugatesmiRNA therapeuticsmicroRNAmicroRNA-34aprostate cancer

Substanzen

Folate Receptor 1FOLR1 protein, humanLigandsMicroRNAsMIRN34 microRNA, humanFolic Acid

Autor:innen und Institutionen

  • Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
  • Experimental Therapeutics (ET) Graduate Program, Roswell Park Comprehensive Cancer Center and the University at Buffalo, Buffalo, NY 14263, USA.
  • Department of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
  • Department of Biological Sciences, Purdue University, West Lafayette, IN 47907, USA.
  • Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.

ORCID-Profile: Wen Jess Li, Xiaozhuo Liu, Joseph A Spernyak, Ahmed M Abdelaal, Kasireddy Sudarshan, Igor Puzanov

Förderung

  • NCI NIH HHS
  • NIH HHS
  • U.S National Institutes of Health (NIH
  • oswell Park Alliance Foundation (RPAF)
  • IVIS Spectrum
  • US NIH
  • DOD

Zitieren

APA

Li, W. J., Wang, Y., Liu, X., Wu, S., Wang, M., Turowski, S. G., Spernyak, J. A., Tracz, A., Abdelaal, A. M., Sudarshan, K., Puzanov, I., Chatta, G., Kasinski, A. L., & Tang, D. G. (2024). Developing Folate-Conjugated miR-34a Therapeutic for Prostate Cancer: Challenges and Promises. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25042123

Vancouver

Li WJ, Wang Y, Liu X, Wu S, Wang M, Turowski SG, et al. Developing Folate-Conjugated miR-34a Therapeutic for Prostate Cancer: Challenges and Promises. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25042123

BibTeX
@article{Li2024,
  author = {Li, Wen Jess and Wang, Yunfei and Liu, Xiaozhuo and Wu, Shan and Wang, Moyi and Turowski, Steven G and Spernyak, Joseph A and Tracz, Amanda and Abdelaal, Ahmed M and Sudarshan, Kasireddy and Puzanov, Igor and Chatta, Gurkamal and Kasinski, Andrea L and Tang, Dean G},
  title = {Developing Folate-Conjugated miR-34a Therapeutic for Prostate Cancer: Challenges and Promises},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25042123}
}
Kostenlos starten →